Senhwa’s NT$500m GEM deal sounds like fresh funding, but the structure is more complicated
Senhwa formalises a NT$500 million GEM share purchase pact, but direct funding, dilution and pipeline execution remain the decisive questions.
Pharma & Biotech
Pharma & Biotech
Can Senhwa’s CX-5461 finally turn cold tumors hot in immunotherapy’s toughest challenge?
Senhwa Biosciences Inc. and BeOne Medicines have signed a clinical supply agreement to explore a novel drug combination aimed at treating hard-to-reach cancers. The collaboration will test Senhwa’s lead compound Pidnarulex (CX-5461), a G-quadruplex stabilizer, in combination with BeOne’s PD-1 inhibitor tislelizumab. The Phase 1b/2a clinical trial will enroll patients with advanced solid tumors, including